Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Decision on Whether Antibiotics Are Manufactured in Japan or Overseas Should be Left to Drug Makers: Govt
The Japanese government said on October 25 that whether medically essential antibiotics and their APIs are manufactured in Japan or overseas should be left entirely to the marketing authorization holders, while stressing the importance of ensuring stable supplies in order…
To read the full story
Related Article
- 1st Working Group Meeting for Prioritization of “Stable Supply Medicines” Set for Early November
October 26, 2020
- MHLW Panel Roughly OKs Report on Stable API Supply Measures
August 31, 2020
- Japan Sketches Out Stable API Supply Measures, Set to Pick Key Drugs from 551 Candidates by March-End
August 4, 2020
- 418 Key Drug Candidates Listed by 36 Societies, Panel to Outline Stable Supply Measures at Next Meeting
June 29, 2020
- Stable Supply Debate Set to Heat Up in Japan, Scientific Societies to Select Key Drugs by June-End
June 9, 2020
- New Stable Supply Panel Wants to Define “Key Drugs” by This Summer
March 30, 2020
- 4 Scientific Societies Submit Proposal to Health Minister to Ensure Stable Antibiotic Supplies
September 4, 2019
- With Continuing Shortage of Cefazolin, Shipments of 21 Substitutes Being Adjusted Too
April 8, 2019
REGULATORY
- Japan Panel Again Defers Male HPV Shots amid Cost-Effectiveness Concerns
October 9, 2026
- Takaichi Defends Off-Year Drug Price Revisions as DPP Calls for Abolition
October 9, 2026
- Japan Orders Contraindication for Adlumiz-Noxafil Combination
October 9, 2026
- Imcivree, Hibsago Get Chuikyo Nod for Home Self-Injection
October 9, 2026
- Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…